doi:10.3969/j.issn.1004-583X.2026.02.016

Abstract

CLC Number:

R542.22

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.02.016

https://www.lchc.cn/EN/Y2026/V41/I2/188

References 37

[1]	Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990-2022[J]. J Am Coll Cardiol, 2023, 82(25): 2350-2473. doi: 10.1016/j.jacc.2023.11.007. pmid: 38092509
[2]	Takeuchi M, Dohi T, Fukase T, et al. Comparison of clinical outcomes between percutaneous coronary intervention for the de novo lesion versus in-stent restenosis lesion[J]. Eur Heart J, 2021, 42(Supplement 1). doi: 10.1007/s12928-021-00792-5.
[3]	Giustino G, Colombo A, Camaj A, et al. Coronary in-stent restenosis[J]. J Am Coll Cardiol, 2022, 80(4): 348-372. doi: 10.1016/j.jacc.2022.05.017. pmid: 35863852
[4]	Korjian S, McCarthy KJ, Larnard EA, et al. Drug-coated balloons in the management of coronary artery disease[J]. Circ Cardiovasc Interv, 2024, 17(5). doi: 10.1161/CIRCINTERVENTIONS.123.013302.
[5]	Muramatsu T, Kozuma K, Tanabe K, et al. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics[J]. Cardiovasc Interv Ther, 2023, 38(2): 166-176. doi: 10.1007/s12928-023-00921-2.
[6]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国慢性冠脉综合征患者诊断及管理指南[J]. 中华心血管病杂志, 2024, 52(6): 589-614. doi: 10.3760/cma.j.cn112148-20240325-00168.
[7]	Van Hemert ND, Stella PR, Rozemeijer R, et al. High bleeding risk in patients undergoing percutaneous coronary intervention with drug-eluting stent implantation: ReCre8 subanalysis[J]. Am Heart J Plus, 2022, 24: 100227. doi: 10.1016/j.ahjo.2022.100227.
[8]	Somsen YBO, Rissanen TT, Hoek R, et al. Application of drug-coated balloons in complex high risk and indicated percutaneous coronary interventions[J]. Catheter Cardiovasc Interv, 2025, 105(2): 494-516. doi: 10.1002/ccd.31316.
[9]	Rheude T, Fitzgerald S, Allali A, et al. Rotational atherectomy or balloon-based techniques to prepare severely calcified coronary lesions[J]. JACC Cardiovasc Interv, 2022, 15(18). doi: 10.1016/j.jcin.2022.07.034.
[10]	Stone GW, Christiansen EH, Ali ZA, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: An updated network meta-analysis[J]. Lancet, 2024, 403(10429): 824-837. doi: 10.1016/S0140-6736(23)02454-6. pmid: 38401549
[11]	Verde N, Ciliberti G, Pittorino L, et al. Contemporary use of drug-coated balloons for coronary angioplasty: A comprehensive review[J]. J Clin Med, 2024, 13(20): 6243. doi: 10.3390/jcm13206243.
[12]	Bhogal S, Hill AP, Merdler I, et al. Drug-coated balloons for coronary artery disease: An updated review with future perspectives[J]. Cardiovasc Revasc Med, 2024. doi: 10.1016/j.carrev.2024.05.027.
[13]	Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(9): 1061-1073. doi: 10.1016/j.jacc.2019.12.046.
[14]	Zhao K, Guo Q, Zhao Z, et al. Clinical value of drug-coated balloon versus second-generation drug-eluting stent for de novo lesions in large coronary arteries: Insights from the real world[J]. BMC Cardiovasc Disord, 2024, 24(1): 1-10. doi: 10.1186/s12872-024-04386-w.
[15]	Ahmed S, Ahmad E, Ahmed M, et al. Paclitaxel-coated balloon catheter versus paclitaxel-eluting stent for the treatment of coronary in-stent restenosis: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2025, 104(15): e42113. doi: 10.1097/MD.0000000000042113.
[16]	Al-Abdouh A, Samadi D, Sukhon F, et al. Paclitaxel-coated balloon versus uncoated balloon angioplasty for coronary in-stent restenosis: A systematic review and meta-analysis of randomized controlled trials[J]. Am J Cardiol, 2024, 231: 82-89. doi: 10.1016/j.amjcard.2024.08.028. pmid: 39222739
[17]	Yeh RW, Shlofmitz R, Moses J, et al. Paclitaxel-coated balloon vs uncoated balloon for coronary in-stent restenosis: The AGENT IDE randomized clinical trial[J]. JAMA, 2024, 331(12). doi: 10.1001/jama.2024.1361.
[18]	Nakamura M, Isawa T, Nakamura S, et al. One-year safety and effectiveness of the Agent paclitaxel-coated balloon for the treatment of small vessel disease and in-stent restenosis[J]. Cardiovasc Interv Ther, 2024, 39(1). doi: 10.1007/s12928-023-00953-8.
[19]	Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease: The RESTORE SVD China randomized trial[J]. JACC Cardiovasc Interv, 2018, 11(23). doi: 10.1016/j.jcin.2018.09.009.
[20]	Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(9). doi: 10.1016/j.jacc.2019.12.046.
[21]	Li Y, Mao Q, Liu H, et al. Effect of paclitaxel-coated balloon angioplasty on side branch lesion and cardiovascular outcomes in patients with de novo true coronary bifurcation lesions undergoing percutaneous coronary intervention[J]. Cardiovasc Drugs Ther, 2022, 36(5). doi: 10.1007/s10557-021-07225-8.
[22]	Eftekhari A, Jensen OL, Veien K, et al. Biolimus-eluting biomatrix stent versus a dual-therapy sirolimus-eluting stent in PCI: SORT OUT XI randomized trial[J]. J Am Coll Cardiol, 2025. doi: 10.1016/j.jacc.2025.05.012.
[23]	Gurgoglione FL, De Gregorio M, Benatti G, et al. Paclitaxel-coated versus sirolimus-coated eluting balloons for percutaneous coronary interventions: Pharmacodynamic properties, clinical evidence, and future perspectives[J]. Future Pharmacol, 2024, 4(4): 775-787. doi: 10.3390/futurepharmacol4040041 URL
[24]	Cortese B, Testa L, Heang TM, et al. Sirolimus-coated balloon in an all-comer population of coronary artery disease patients: The EASTBOURNE prospective registry[J]. JACC Cardiovasc Interv, 2023, 16(14). doi: 10.1016/j.jcin.2023.05.005.
[25]	Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J]. N Engl J Med, 2006, 355(20): 2113-2124. doi: 10.1056/NEJMoa061254.
[26]	Pan L, Lu W, Han Z, et al. Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis[J]. Front Cardiovasc Med, 2022, 9: 1028007. doi: 10.3389/fcvm.2022.1028007.
[27]	Uskela S, Kärkkäinen JM, Eränen J, et al. Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndromes: An all-comers registry study[J]. Catheter Cardiovasc Interv, 2019, 93(5): 893-900. doi: 10.1002/ccd.27950.
[28]	Qin Q, Chen L, Ge L, et al. Long-term clinical outcomes of drug-coated balloon for the management of chronic total occlusions[J]. Coron Artery Dis, 2023, 34(8): 555. doi: 10.1097/MCA.0000000000001288.
[29]	Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: Are lesions clinically stable from 12 to 36 months?[J]. EuroIntervention, 2013, 9(5): 620-628. doi: 10.4244/EIJV9I5A99. pmid: 24058078
[30]	Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J, 2014, 35(37). doi: 10.1093/eurheartj/ehu278.
[31]	Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
[32]	Nijhoff F, Agostoni P, Belkacemi A, et al. Primary percutaneous coronary intervention by drug-eluting balloon angioplasty: The nonrandomized fourth arm of the DEB-AMI (drug-eluting balloon in ST-segment elevation myocardial infarction) trial[J]. Catheter Cardiovasc Interv, 2015, 86: S34-S44. doi: 10.1002/ccd.25603.
[33]	Vos NS, Dirksen MT, Vink MA, et al. Safety and feasibility of a paclitaxel-eluting balloon angioplasty in primary percutaneous coronary intervention in Amsterdam (PAPPA): One-year clinical outcome of a pilot study[J]. EuroIntervention, 2014, 10(5): 584-590. doi: 10.4244/EIJV10I5A101. pmid: 25256200
[34]	Vos NS, Van Der Schaaf RJ, Amoroso G, et al. Revascularization with paclitaxel-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarction-a randomized controlled trial: Rationale and design of the REVELATION trial[J]. Catheter Cardiovasc Interv, 2016, 87(7): 1213-1221.
[35]	Vos NS, Fagel ND, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction[J]. JACC Cardiovasc Interv, 2019, 12(17): 1691-1699. doi: 10.1016/j.jcin.2019.04.016.
[36]	Niehe SR, Vos NS, Van Der Schaaf RJ, et al. 5-Year clinical outcomes of paclitaxel-coated balloon angioplasty vs DES in acute MI: The REVELATION trial[J]. JACC Cardiovasc Interv, 2024, 17(9): 1185-1186. doi: 10.1016/j.jcin.2024.03.012.
[37]	Gao C, He X, Ouyang F, et al. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): An open-label, randomised, non-inferiority trial[J]. Lancet, 2024, 404(10457): 1040-1050. doi: 10.1016/S0140-6736(24)01594-0. pmid: 39236727

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 37

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ouyang Weili, Jiang Yile. TyG and TyG-BMI indices predict major adverse cardiovascular events after emergency revascularization for acute myocardial infarction [J]. Clinical Focus, 2026, 41(1): 12-17.
[2]	Shi Huili, Wang Peipei, Ma Dongpu, Yang Yanpeng. Analysis of factors influencing extracorporeal membrane oxygenation combined with intra-aortic balloon pump in the treatment of cardiac shock [J]. Clinical Focus, 2025, 40(11): 973-977.
[3]	Liu Ping, Yu Meng, Liu Mingxin, Li Wenfeng. Correlation of new inflammatory indicators in the complete blood count with major adverse cardiovascular events in patients with acute anterior wall ST-segment elevation myocardial infarction after percutaneous coronary intervention [J]. Clinical Focus, 2025, 40(5): 400-407.
[4]	Zhang Lei, Li Xin, Guo Zhenfeng. Efficacy and safety of intracoronary injection of teneplase versus tirofiban on the treatment of acute ST-segment elevation myocardial infarction [J]. Clinical Focus, 2024, 39(7): 598-602.
[5]	Li Yanan, Zhang Hongyu. Clinical study of the efficacy of intracoronary injections of low-dose prourokinase through the tail of the balloon on acute ST-segment elevation myocardial infarction patients undergoing percuteneous coronary intervention [J]. Clinical Focus, 2024, 39(6): 518-523.
[6]	. [J]. Clinical Focus, 2024, 39(3): 264-268.
[7]	Zhang Canna, Xiang Lu, Luo Yaxiong. Electrocardiographic findings of the spiked helmet sign: A case report and literature review [J]. Clinical Focus, 2023, 38(5): 444-447.
[8]	Yan Haiyan, Ding Yankui, JiaHongjing , WangJiyuan , Zhang Xuewei, Hu Yinjie, Chu Junjie, Hu Hongyan, Guo Gaofeng. Correlation of pre-hospital heparinization combined with one pack of drugs and revascularization in patients with acute ST-segment elevation myocardial infarction [J]. Clinical Focus, 2023, 38(3): 232-236.
[9]	Li Nana, Jiang Shan. Predictive values of serum homocysteine, cystatin C and high sensitive C-reactive protein levels on heart failure after percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction [J]. Clinical Focus, 2023, 38(2): 121-125.
[10]	Wang Jiaqi, Gao Man, Zhang Feifei, Li Yingxiao, Dang Yi, Qi Xiaoyong. Predicting value of neutrophil to lymphocyte ratio combined with GRACE score on in-hospital major adverse cardiovascular events of postoperative PCI in acute STEMI patients [J]. Clinical Focus, 2022, 37(5): 412-417.
[11]	. [J]. Clinical Focus, 2021, 36(10): 956-960.
[12]	Shi Jun, Liu Xinbing, Bai Yanyan, Yue Dandan, Wang Xiaoqing, Liu Tianhua, Feng Liuliu. Influencing factors of myocardial microcirculation perfusion disorder after percutaneous coronary intervention in acute myocardial infarction and relationship with lactic acid [J]. Clinical Focus, 2021, 36(5): 402-407.
[13]	He Na, Li Minxian, Zhang Qi, Xu Fang, Zhang Chenfeng, Song Da. Effects of Tongxinluo Capsules on myocardial microperfusion in patients free of reflow after PCI and long-term efficacy and safety [J]. Clinical Focus, 2021, 36(2): 129-133.
[14]	Luo Kaifeng, Feng Chuanjie. The factors influencing the prognosis of STsegment elevation myocardial infarction after coronary intervention A meta analysis [J]. Clinical Focus, 2020, 35(12): 1067-1077.
[15]	. [J]. Clinical Focus, 2016, 31(3): 340-341.